AU729598B2 - Electromagnetic therapeutic treatment device and methods of using same - Google Patents
Electromagnetic therapeutic treatment device and methods of using same Download PDFInfo
- Publication number
- AU729598B2 AU729598B2 AU63883/96A AU6388396A AU729598B2 AU 729598 B2 AU729598 B2 AU 729598B2 AU 63883/96 A AU63883/96 A AU 63883/96A AU 6388396 A AU6388396 A AU 6388396A AU 729598 B2 AU729598 B2 AU 729598B2
- Authority
- AU
- Australia
- Prior art keywords
- magnetic
- poles
- flux
- treatment device
- bodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000011282 treatment Methods 0.000 title claims description 318
- 230000001225 therapeutic effect Effects 0.000 title claims description 207
- 238000000034 method Methods 0.000 title claims description 54
- 230000005291 magnetic effect Effects 0.000 claims description 874
- 230000004907 flux Effects 0.000 claims description 785
- 241001465754 Metazoa Species 0.000 claims description 120
- 241000282414 Homo sapiens Species 0.000 claims description 86
- 208000002193 Pain Diseases 0.000 claims description 64
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 63
- 230000036407 pain Effects 0.000 claims description 59
- 208000027418 Wounds and injury Diseases 0.000 claims description 52
- 206010052428 Wound Diseases 0.000 claims description 37
- 229910001018 Cast iron Inorganic materials 0.000 claims description 34
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 33
- 230000035876 healing Effects 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 206010010904 Convulsion Diseases 0.000 claims description 24
- 210000004165 myocardium Anatomy 0.000 claims description 24
- 229910052782 aluminium Inorganic materials 0.000 claims description 23
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 23
- 206010030113 Oedema Diseases 0.000 claims description 21
- 230000030833 cell death Effects 0.000 claims description 21
- 230000008093 supporting effect Effects 0.000 claims description 20
- 210000004556 brain Anatomy 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 15
- 230000006378 damage Effects 0.000 claims description 15
- 208000014674 injury Diseases 0.000 claims description 15
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 14
- 230000000149 penetrating effect Effects 0.000 claims description 14
- 206010048962 Brain oedema Diseases 0.000 claims description 13
- 206010021143 Hypoxia Diseases 0.000 claims description 13
- 230000017531 blood circulation Effects 0.000 claims description 13
- 208000006752 brain edema Diseases 0.000 claims description 13
- 229910052751 metal Inorganic materials 0.000 claims description 12
- 239000002184 metal Substances 0.000 claims description 12
- 238000001356 surgical procedure Methods 0.000 claims description 12
- 230000001146 hypoxic effect Effects 0.000 claims description 11
- 230000001684 chronic effect Effects 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 10
- 230000008961 swelling Effects 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 9
- 230000005294 ferromagnetic effect Effects 0.000 claims description 9
- 230000002107 myocardial effect Effects 0.000 claims description 8
- 230000033001 locomotion Effects 0.000 claims description 7
- 230000003389 potentiating effect Effects 0.000 claims description 7
- 206010008479 Chest Pain Diseases 0.000 claims description 6
- 206010040642 Sickle cell anaemia with crisis Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 5
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 239000003990 capacitor Substances 0.000 claims description 5
- 208000037273 Pathologic Processes Diseases 0.000 claims description 4
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 230000008058 pain sensation Effects 0.000 claims description 4
- 230000009054 pathological process Effects 0.000 claims description 4
- 230000007310 pathophysiology Effects 0.000 claims description 4
- 230000002441 reversible effect Effects 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 230000001965 increasing effect Effects 0.000 description 24
- 239000004020 conductor Substances 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 230000003068 static effect Effects 0.000 description 20
- 230000006698 induction Effects 0.000 description 19
- 230000001276 controlling effect Effects 0.000 description 16
- 230000001105 regulatory effect Effects 0.000 description 16
- 229910052802 copper Inorganic materials 0.000 description 15
- 239000010949 copper Substances 0.000 description 15
- 230000007423 decrease Effects 0.000 description 14
- 210000002569 neuron Anatomy 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 208000006011 Stroke Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 9
- 239000003381 stabilizer Substances 0.000 description 9
- 230000002459 sustained effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 230000003466 anti-cipated effect Effects 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- 238000012544 monitoring process Methods 0.000 description 8
- 210000000115 thoracic cavity Anatomy 0.000 description 8
- 229910000576 Laminated steel Inorganic materials 0.000 description 7
- 206010061592 cardiac fibrillation Diseases 0.000 description 7
- 210000002421 cell wall Anatomy 0.000 description 7
- 230000002600 fibrillogenic effect Effects 0.000 description 7
- 150000002500 ions Chemical class 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 108090000312 Calcium Channels Chemical group 0.000 description 6
- 102000003922 Calcium Channels Human genes 0.000 description 6
- 230000000747 cardiac effect Effects 0.000 description 6
- 238000010304 firing Methods 0.000 description 6
- 238000009413 insulation Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000007257 malfunction Effects 0.000 description 5
- 239000008177 pharmaceutical agent Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000007056 sickle cell anemia Diseases 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 4
- 108010052164 Sodium Channels Proteins 0.000 description 4
- 102000018674 Sodium Channels Human genes 0.000 description 4
- -1 as for example Substances 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 230000009163 spontaneous depolarization Effects 0.000 description 4
- 208000005809 status epilepticus Diseases 0.000 description 4
- 230000002889 sympathetic effect Effects 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- 102000013138 Drug Receptors Human genes 0.000 description 3
- 108010065556 Drug Receptors Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 230000010799 Receptor Interactions Effects 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000010953 base metal Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 230000005672 electromagnetic field Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000000297 inotrophic effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000003475 lamination Methods 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 3
- 238000004804 winding Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000002057 chronotropic effect Effects 0.000 description 2
- 238000011443 conventional therapy Methods 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000000940 electromagnetic therapy Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 210000001624 hip Anatomy 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 238000013150 knee replacement Methods 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000004081 narcotic agent Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940124583 pain medication Drugs 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- BCBHDSLDGBIFIX-UHFFFAOYSA-M 4-[(2-hydroxyethoxy)carbonyl]benzoate Chemical compound OCCOC(=O)C1=CC=C(C([O-])=O)C=C1 BCBHDSLDGBIFIX-UHFFFAOYSA-M 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 206010003175 Arterial spasm Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 229910000976 Electrical steel Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 230000005355 Hall effect Effects 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 229910001030 Iron–nickel alloy Inorganic materials 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002869 anti-sickling effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940124574 antisickling agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000009973 brain hypoxia - ischemia Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001862 defibrillatory effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002653 magnetic therapy Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229910000889 permalloy Inorganic materials 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000003195 sodium channel blocking agent Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/008—Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Magnetic Treatment Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1996/010590 WO1997000639A2 (en) | 1995-06-19 | 1996-06-19 | Electromagnetic treatment device and methods of using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6388396A AU6388396A (en) | 1997-01-22 |
| AU729598B2 true AU729598B2 (en) | 2001-02-08 |
Family
ID=22255360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU63883/96A Expired AU729598B2 (en) | 1996-06-19 | 1996-06-19 | Electromagnetic therapeutic treatment device and methods of using same |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPH11513907A (de) |
| AT (1) | ATE303177T1 (de) |
| AU (1) | AU729598B2 (de) |
| DE (1) | DE69635137T2 (de) |
| HK (1) | HK1021946A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010028115B4 (de) * | 2010-04-22 | 2013-10-02 | Siemens Aktiengesellschaft | Vorrichtung zur Therapie der Herzmuskelinsuffizienz |
| ES1073912Y (es) * | 2010-10-14 | 2011-10-04 | Pellicer Carlos F | Equipo medico |
| US9789330B1 (en) | 2014-10-28 | 2017-10-17 | Knowledge Technologies, LLC | Apparatus for transcranial magnetic stimulation |
| DE102017011939A1 (de) | 2017-12-22 | 2019-06-27 | HE-Invent GmbH & Co. KG | Funktionsmöbel |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081109A2 (de) * | 1981-12-04 | 1983-06-15 | Energy-Pak Ltd. | Magnetisches Heilpflaster für die Behandlung grösserer Flächen |
-
1996
- 1996-06-19 JP JP9503923A patent/JPH11513907A/ja not_active Withdrawn
- 1996-06-19 AU AU63883/96A patent/AU729598B2/en not_active Expired
- 1996-06-19 AT AT96923351T patent/ATE303177T1/de not_active IP Right Cessation
- 1996-06-19 DE DE69635137T patent/DE69635137T2/de not_active Expired - Lifetime
-
2000
- 2000-02-18 HK HK00100976A patent/HK1021946A1/xx not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0081109A2 (de) * | 1981-12-04 | 1983-06-15 | Energy-Pak Ltd. | Magnetisches Heilpflaster für die Behandlung grösserer Flächen |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6388396A (en) | 1997-01-22 |
| DE69635137T2 (de) | 2006-06-22 |
| JPH11513907A (ja) | 1999-11-30 |
| ATE303177T1 (de) | 2005-09-15 |
| DE69635137D1 (de) | 2005-10-06 |
| HK1021946A1 (en) | 2000-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6042531A (en) | Electromagnetic therapeutic treatment device and methods of using same | |
| US9764154B2 (en) | Method and morphologically adaptable apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity | |
| US6461288B1 (en) | Method and apparatus for altering the charge distribution upon living membranes with functional stabilization of the membrane physical electrical integrity | |
| CA2056448C (en) | Electromagnetic treatment device | |
| ES2546081T3 (es) | Aparato de terapia de convulsiones | |
| US20090099405A1 (en) | Monophasic multi-coil arrays for trancranial magnetic stimulation | |
| US20130267763A1 (en) | Transverse transcranial magnetic stimulation coil placement for improved analgesia | |
| JP4545722B2 (ja) | 電磁気治療用処置装置及びその使用方法 | |
| AU729598B2 (en) | Electromagnetic therapeutic treatment device and methods of using same | |
| KR100479568B1 (ko) | 전자기치료장치 | |
| EP0930915B1 (de) | Apparatur zur elektromagnetischen therapie | |
| EP1030712B1 (de) | Gerät zur veränderung der ladungsverteilung auf lebenden membranen mit funktioneller stabilisierung der physikalischen integrität der membran | |
| KR100433939B1 (ko) | 연속펄스의비조절비파열식신경자극기를사용하여효율및지각허용성을개선시키는방법 | |
| Lanocha et al. | Transcranial Magnetic Stimulation and Other Neuromodulation Therapies | |
| Hussein | Evaluation of Treatment of Neuronal Damage with Extracranial Magnetic Field in A Rabbit Model of Stroke | |
| IL233203B2 (en) | Magnetic stimulation through the pulley |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |